Recent developments in therapeutic cancer vaccines

Michael A. Morse, Stephen (Steve) Chui, Amy Hobeika, H. Kim Lyerly, Timothy Clay

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Therapeutic cancer vaccines ae being developed with the intention of treating existing tumors or preventing tumor recurrence. While the results of clinical trials, predominantly in the metastatic setting have been sobering, the central hypothesis of active immunotherapy i.e. that the human immune system can be activated to recognize and destroy tumor cells, remains a viable one. We believe that a fundamental shift in how clinical trials are performed, and what concepts they test is required to make meaningful strides towards future clinical use of cancer vaccines. First, we must reappraise whether the metastatic setting is the appropriate arena to test these agents. Second, we must arrive at a consensus on the most important biologic endpoints and rapidly test vaccines for their ability to achieve these endpoints. Third, we need to expend more effort on understanding how to manipulate the immune system beyond the initial stimulation provided by a vaccine. Fourth, in order to permit comparison of results across different studies, it would be helpful to narrow down the large number of vaccine platforms. We will discuss the current state of development of cancer vaccines and the relevance for future clinical use of these agents to treat and prevent cancers.

Original languageEnglish (US)
Pages (from-to)108-113
Number of pages6
JournalNature Clinical Practice Oncology
Volume2
Issue number2
DOIs
StatePublished - Feb 2005
Externally publishedYes

Fingerprint

Cancer Vaccines
Vaccines
Immune System
Neoplasms
Clinical Trials
Active Immunotherapy
Aptitude
Therapeutics
Consensus
Recurrence

Keywords

  • Antibody
  • Dendritic cell
  • Immunotherapy
  • T cell
  • Viral vector

ASJC Scopus subject areas

  • Oncology

Cite this

Morse, M. A., Chui, S. S., Hobeika, A., Lyerly, H. K., & Clay, T. (2005). Recent developments in therapeutic cancer vaccines. Nature Clinical Practice Oncology, 2(2), 108-113. https://doi.org/10.1038/ncponc0098

Recent developments in therapeutic cancer vaccines. / Morse, Michael A.; Chui, Stephen (Steve); Hobeika, Amy; Lyerly, H. Kim; Clay, Timothy.

In: Nature Clinical Practice Oncology, Vol. 2, No. 2, 02.2005, p. 108-113.

Research output: Contribution to journalArticle

Morse, MA, Chui, SS, Hobeika, A, Lyerly, HK & Clay, T 2005, 'Recent developments in therapeutic cancer vaccines', Nature Clinical Practice Oncology, vol. 2, no. 2, pp. 108-113. https://doi.org/10.1038/ncponc0098
Morse, Michael A. ; Chui, Stephen (Steve) ; Hobeika, Amy ; Lyerly, H. Kim ; Clay, Timothy. / Recent developments in therapeutic cancer vaccines. In: Nature Clinical Practice Oncology. 2005 ; Vol. 2, No. 2. pp. 108-113.
@article{6bcd9c32b0d94e06ab1a198053f61c54,
title = "Recent developments in therapeutic cancer vaccines",
abstract = "Therapeutic cancer vaccines ae being developed with the intention of treating existing tumors or preventing tumor recurrence. While the results of clinical trials, predominantly in the metastatic setting have been sobering, the central hypothesis of active immunotherapy i.e. that the human immune system can be activated to recognize and destroy tumor cells, remains a viable one. We believe that a fundamental shift in how clinical trials are performed, and what concepts they test is required to make meaningful strides towards future clinical use of cancer vaccines. First, we must reappraise whether the metastatic setting is the appropriate arena to test these agents. Second, we must arrive at a consensus on the most important biologic endpoints and rapidly test vaccines for their ability to achieve these endpoints. Third, we need to expend more effort on understanding how to manipulate the immune system beyond the initial stimulation provided by a vaccine. Fourth, in order to permit comparison of results across different studies, it would be helpful to narrow down the large number of vaccine platforms. We will discuss the current state of development of cancer vaccines and the relevance for future clinical use of these agents to treat and prevent cancers.",
keywords = "Antibody, Dendritic cell, Immunotherapy, T cell, Viral vector",
author = "Morse, {Michael A.} and Chui, {Stephen (Steve)} and Amy Hobeika and Lyerly, {H. Kim} and Timothy Clay",
year = "2005",
month = "2",
doi = "10.1038/ncponc0098",
language = "English (US)",
volume = "2",
pages = "108--113",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Recent developments in therapeutic cancer vaccines

AU - Morse, Michael A.

AU - Chui, Stephen (Steve)

AU - Hobeika, Amy

AU - Lyerly, H. Kim

AU - Clay, Timothy

PY - 2005/2

Y1 - 2005/2

N2 - Therapeutic cancer vaccines ae being developed with the intention of treating existing tumors or preventing tumor recurrence. While the results of clinical trials, predominantly in the metastatic setting have been sobering, the central hypothesis of active immunotherapy i.e. that the human immune system can be activated to recognize and destroy tumor cells, remains a viable one. We believe that a fundamental shift in how clinical trials are performed, and what concepts they test is required to make meaningful strides towards future clinical use of cancer vaccines. First, we must reappraise whether the metastatic setting is the appropriate arena to test these agents. Second, we must arrive at a consensus on the most important biologic endpoints and rapidly test vaccines for their ability to achieve these endpoints. Third, we need to expend more effort on understanding how to manipulate the immune system beyond the initial stimulation provided by a vaccine. Fourth, in order to permit comparison of results across different studies, it would be helpful to narrow down the large number of vaccine platforms. We will discuss the current state of development of cancer vaccines and the relevance for future clinical use of these agents to treat and prevent cancers.

AB - Therapeutic cancer vaccines ae being developed with the intention of treating existing tumors or preventing tumor recurrence. While the results of clinical trials, predominantly in the metastatic setting have been sobering, the central hypothesis of active immunotherapy i.e. that the human immune system can be activated to recognize and destroy tumor cells, remains a viable one. We believe that a fundamental shift in how clinical trials are performed, and what concepts they test is required to make meaningful strides towards future clinical use of cancer vaccines. First, we must reappraise whether the metastatic setting is the appropriate arena to test these agents. Second, we must arrive at a consensus on the most important biologic endpoints and rapidly test vaccines for their ability to achieve these endpoints. Third, we need to expend more effort on understanding how to manipulate the immune system beyond the initial stimulation provided by a vaccine. Fourth, in order to permit comparison of results across different studies, it would be helpful to narrow down the large number of vaccine platforms. We will discuss the current state of development of cancer vaccines and the relevance for future clinical use of these agents to treat and prevent cancers.

KW - Antibody

KW - Dendritic cell

KW - Immunotherapy

KW - T cell

KW - Viral vector

UR - http://www.scopus.com/inward/record.url?scp=20344405453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344405453&partnerID=8YFLogxK

U2 - 10.1038/ncponc0098

DO - 10.1038/ncponc0098

M3 - Article

VL - 2

SP - 108

EP - 113

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 2

ER -